This study looks at the long-term safety and effects of a drug called ALZ-801 in people with early Alzheimer's disease who have a specific gene (APOE4/4). About 163 participants who completed an earlier phase 3 trial will take the drug for up to 2 more years. Researchers will tra…
Phase: PHASE3 • Sponsor: Alzheon Inc. • Aim: Disease control
Last updated Jun 17, 2026 12:03 UTC